Interleukin-11 receptor is an alternative α-receptor for interleukin-6 and the chimeric cytokine IC7.
IL‐11
cross‐talk
cytokine
gp130
interleukin 6
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
revised:
30
07
2024
received:
29
02
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
The cytokine interleukin 6 (IL-6) signals via the IL-6 α-receptor (IL-6Rα or IL-6R) in complex with the gp130 β-receptor. Cell type restricted expression of the IL-6R limits the action of IL-6 mainly to hepatocytes and some immune cells. Here, we show that IL-6 also binds to the IL-11 α receptor (IL-11Rα or IL-11R) and induces signaling via IL-11R:gp130 complexes, albeit with a lower affinity compared to IL-11. Antagonistic antibodies directed against IL-11R, but not IL-6R, inhibit IL-6 signaling via IL-11R:gp130 receptor complexes. Notably, IL-11 did not cross-react with IL-6R. IL-11R has also been identified as an alternative α receptor for the CNTF/IL-6-derived chimeric cytokine IC7, which has recently been shown to induce weight loss in mice. Accordingly, the effects of therapeutic monoclonal antibodies against IL-6 or IL-6R, which both block IL-6 signaling, may be slightly different. These findings provide new insights into IL-6 signaling and therefore offer new potential therapeutic intervention options in the future.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHE 907/5-1
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHE 907/6-1
Informations de copyright
© 2024 The Author(s). The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Garbers C, Hermanns H, Schaper F, Müller Newen G, Grötzinger J, Rose John S & Scheller J (2012) Plasticity and cross‐talk of interleukin 6‐type cytokines. Cytokine Growth Factor Rev 23, 85–97.
Garbers C & Scheller J (2013) Interleukin‐6 and interleukin‐11: same same but different. Biol Chem 394, 1145–1161.
Kang S, Narazaki M, Metwally H & Kishimoto T (2020) Historical overview of the interleukin‐6 family cytokine. J Exp Med 217, e20190347.
Heinrich PC, Behrmann I, Müller‐Newen G, Schaper F & Graeve L (1998) Interleukin‐6‐type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2), 297–314.
Taga T & Kishimoto T (1997) Gp130 and the interleukin‐6 family of cytokines. Annu Rev Immunol 15, 797–819.
Grötzinger J, Kernebeck T, Kallen KJ & Rose‐John S (1999) IL‐6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 380, 803–813.
Garbers C, Spudy B, Aparicio‐Siegmund S, Waetzig GH, Sommer J, Hölscher C, Rose‐John S, Grötzinger J, Lorenzen I & Scheller J (2013) An interleukin‐6 receptor‐dependent molecular switch mediates signal transduction of the IL‐27 cytokine subunit p28 (IL‐30) via a gp130 protein receptor homodimer. J Biol Chem 288, 4346–4354.
McFarland‐Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, Kozma SC & Drew AF (2010) Differences in wound healing in mice with deficiency of IL‐6 versus IL‐6 receptor. J Immunol 184, 7219–7228.
Sommer J, Engelowski E, Baran P, Garbers C, Floss DM & Scheller J (2014) Interleukin‐6, but not the interleukin‐6 receptor plays a role in recovery from dextran sodium sulfate‐induced colitis. Int J Mol Med 34, 651–660.
Minafra AR, Chadt A, Rafii P, Al‐Hasani H, Behnke K & Scheller J (2022) Interleukin 6 receptor is not directly involved in regulation of body weight in diet‐induced obesity with and without physical exercise. Front Endocrinol 13, 1028808.
Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C & Jansson JO (2002) Interleukin‐6‐deficient mice develop mature‐onset obesity. Nat Med 8, 75–79.
Rose‐John S (2020) Interleukin‐6 signalling in health and disease. F1000Res 9, doi: 10.12688/f1000research.26058.1
Lokau J, Kespohl B, Kirschke S & Garbers C (2022) The role of proteolysis in interleukin‐11 signaling. Biochim Biophys Acta Mol Cell Res 1869, 119135.
Putoczki T & Ernst M (2010) More than a sidekick: the IL‐6 family cytokine IL‐11 links inflammation to cancer. J Leukoc Biol 88, 1109–1117.
Nishina T, Komazawa‐Sakon S, Yanaka S, Piao X, Zheng DM, Piao JH, Kojima Y, Yamashina S, Sano E, Putoczki T et al. (2012) Interleukin‐11 links oxidative stress and compensatory proliferation. Sci Signal 5, ra5.
Sims NA, Jenkins BJ, Nakamura A, Quinn JM, Li R, Gillespie MT, Ernst M, Robb L & Martin TJ (2005) Interleukin‐11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 20, 1093–1102.
Agthe M, Garbers Y, Putoczki T & Garbers C (2017) Interleukin‐11 classic but not trans‐signaling is essential for fertility in mice. Placenta 57, 13–16.
Nitz R, Lokau J, Aparicio‐Siegmund S, Scheller J & Garbers C (2015) Modular organization of interleukin‐6 and interleukin‐11 α‐receptors. Biochimie 119, 175–182.
Lokau J, Nitz R, Agthe M, Monhasery N, Aparicio‐Siegmund S, Schumacher N, Wolf J, Möller‐Hackbarth K, Waetzig GH, Grötzinger J et al. (2016) Proteolytic cleavage governs interleukin‐11 trans‐signaling. Cell Rep 14, 1761–1773.
Metz S, Wiesinger M, Vogt M, Lauks H, Schmalzing G, Heinrich P & Müller‐Newen G (2007) Characterization of the interleukin (IL)‐6 inhibitor IL‐6‐RFP: fused receptor domains act as high affinity cytokine‐binding proteins. J Biol Chem 282, 1238–1248.
Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J & Rose‐John S (1997) I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15, 142–145.
Pflanz S, Tacken I, Grötzinger J, Jacques Y, Minvielle S, Dahmen H, Heinrich PC & Müller‐Newen G (1999) A fusion protein of interleukin‐11 and soluble interleukin‐11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett 450, 117–122.
Lieschke GJ, Rao PK, Gately MK & Mulligan RC (1997) Bioactive murine and human interleukin‐12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 15, 35–40.
Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath M & Rose‐John S (2001) Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses. Eur J Biochem 268, 160–167.
Kallen KJ, Grotzinger J, Lelievre E, Vollmer P, Aasland D, Renne C, Mullberg J, Myer zum Buschenfelde KH, Gascan H & Rose‐John S (1999) Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor‐binding site from ciliary neurotrophic factor to interleukin‐6. J Biol Chem 274, 11859–11867.
Rafii P, Seibel C, Weitz HT, Ettich J, Minafra AR, Petzsch P, Lang A, Floss DM, Behnke K, Köhrer K et al. (2023) Cytokimera GIL‐11 rescued IL‐6R deficient mice from partial hepatectomy‐induced death by signaling via non‐natural gp130:LIFR:IL‐11R complexes. Commun Biol 6, 418.
Adam N, Rabe B, Suthaus J, Grötzinger J, Rose‐John S & Scheller J (2009) Unraveling viral interleukin‐6 binding to gp130 and activation of STAT‐signaling pathways independently of the interleukin‐6 receptor. J Virol 83, 5117–5126.
Li Y, Feng J, Song S, Li H, Yang H, Zhou B, Li Y, Yue Z, Lian H, Liu L et al. (2020) gp130 controls cardiomyocyte proliferation and heart regeneration. Circulation 142, 967–982.
Findeisen M, Allen T, Henstridge D, Kammoun H, Brandon A, Baggio L, Watt K, Pal M, Cron L, Estevez E et al. (2019) Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574, 63–68.
Curtis DJ, Hilton DJ, Roberts B, Murray L, Nicola N & Begley CG (1997) Recombinant soluble interleukin‐11 (IL‐11) receptor alpha‐chain can act as an IL‐11 antagonist. Blood 90, 4403–4412.
Hilton DJ, Hilton AA, Raicevic A, Rakar S, Harrison‐Smith M, Gough NM, Begley CG, Metcalf D, Nicola NA & Willson TA (1994) Cloning of a murine IL‐11 receptor alpha‐chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 13, 4765–4775.
Dams‐Kozlowska H, Gryska K, Kwiatkowska‐Borowczyk E, Izycki D, Rose‐John S & Mackiewicz A (2012) A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotechnol 12, 8.
Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grotzinger J, Rose‐John S & Kallen KJ (2003) Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin‐6 receptor can serve as an alpha‐receptor for CTNF. J Biol Chem 278, 9528–9535.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C et al. (2000) Blockade of interleukin 6 trans signaling suppresses T‐cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6, 583–588.
Rose‐John S, Jenkins BJ, Garbers C, Moll JM & Scheller J (2023) Targeting IL‐6 trans‐signalling: past, present and future prospects. Nat Rev Immunol 23, 666–681.
Waage A, Brandtzaeg P, Halstensen A, Kierulf P & Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169, 333–338.
Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, Mueller‐Heine A, Chalaris A, Scheller J, Rose‐John S et al. (2011) Selective blockade of interleukin‐6 trans‐signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 39, 1407–1413.
Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C & Pape HC (2008) Correlation between IL‐6 levels and the systemic inflammatory response score: can an IL‐6 cutoff predict a SIRS state? J Trauma 65, 646–652.
Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, Laberge RM, Vijg J, Van Steeg H, Dollé ME et al. (2014) An essential role for senescent cells in optimal wound healing through secretion of PDGF‐AA. Dev Cell 31, 722–733.
Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch‐Nolte F, Rose‐John S & Scheller J (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin‐6 (IL‐6) trans‐signaling and novel role of ADAM10 in inducible IL‐6 receptor shedding. J Biol Chem 286, 14804–14811.
Floss DM, Mrotzek S, Klöcker T, Schröder J, Grötzinger J, Rose‐John S & Scheller J (2013) Identification of canonical tyrosine‐dependent and non‐canonical tyrosine‐independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor. J Biol Chem 288, 19386–19400.
Schroers A, Hecht O, Kallen KJ, Pachta M, Rose‐John S & Grötzinger J (2005) Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci 14, 783–790.
Berg AF, Ettich J, Weitz HT, Krusche M, Floss DM, Scheller J & Moll JM (2021) Exclusive inhibition of IL‐6 trans‐signaling by soluble gp130FlyRFc. Cytokine X 3, 100058.
Görtz D, Braun GS, Maruta Y, Djudjaj S, van Roeyen CR, Martin IV, Küster A, Schmitz‐Van de Leur H, Scheller J, Ostendorf T et al. (2015) Anti‐interleukin‐6 therapy through application of a monogenic protein inhibitor via gene delivery. Sci Rep 5, 14685.
Heise D, Derrac Soria A, Hansen S, Dambietz C, Akbarzadeh M, Berg AF, Waetzig GH, Jones SA, Dvorsky R, Ahmadian MR et al. (2021) Selective inhibition of IL‐6 trans‐signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Sci Signal 14, eabc3480.
Aparicio‐Siegmund S, Moll JM, Lokau J, Grusdat M, Schröder J, Plöhn S, Rose‐John S, Grötzinger J, Lang PA, Scheller J et al. (2014) Recombinant p35 from bacteria can form interleukin (IL‐)12, but not IL‐35. PLoS One 9, e107990.
Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S & Steinegger M (2022) ColabFold: making protein folding accessible to all. Nat Methods 19, 679–682.